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Background: Elevated triglycerides (TGs) are a common lipid disorder in the US and are associ-
ated with comorbidities such as pancreatitis, obesity, type 2 diabetes, and metabolic   syndrome. 
TGs are generally elevated in postmenopausal women compared with premenopausal women. 
Meta-analysis has shown that elevated TGs are associated with an increased risk of coronary 
heart disease (CHD).
Objective: This article provides a general overview of TG metabolism and reviews data on the 
epidemiology and risk of elevated TGs in women, as pregnancy and menopause, in particular, 
have been associated with unfavorable changes in the lipoprotein profile, including elevations in 
TGs. In addition, this review seeks to explain the recommended TG goals and treatment options 
for hypertriglyceridemia with an emphasis on severe hypertriglyceridemia (TGs $ 500 mg/dL) 
and its respective treatment with prescription omega-3-acid ethyl esters (P-OM3).
Methods: MedLine was searched for articles published through August 2009 using the terms 
“hypertriglyceridemia” and “dyslipidemia”, with subheadings for “prevalence”, “women”, 
“treatment”, “guidelines”, “risk”, and “omega-3 fatty acids”. Publications discussing the epi-
demiology of hypertriglyceridemia, CHD risk, treatment guidelines for lipid management, or 
clinical trials involving P-OM3 were selected for review. The reference lists of relevant articles 
were also examined for additional citations.
Results: Hypertriglyceridemia is associated with increased CHD risk. Women, especially 
those with polycystic ovarian syndrome, type 2 diabetes, or who are postmenopausal, should be 
monitored regularly for the impact of hypertriglyceridemia on their lipid profile.   Cardiovascular 
risk of TGs can be indirectly assessed by monitoring non-high-density lipoprotein cholesterol 
(non-HDL-C) levels. There are multiple sets of guidelines providing recommendations for desir-
able low-density lipoprotein cholesterol, TG, and non-HDL-C levels. Treatment of hypertrig-
lyceridemia includes lifestyle interventions and, if needed, pharmacologic therapy. In patients 
with severe hypertriglyceridemia, P-OM3 can reduce TGs by up to 45%.
Conclusion: Physicians should regularly monitor the lipid profile of their female patients. Any 
lipid abnormality should be managed promptly according to established guidelines. P-OM3 
provide a well-tolerated option for the treatment of severe hypertriglyceridemia.
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Introduction
Lipid abnormalities, including elevated cholesterol or triglyceride (TG) concentra-
tions, are a common finding among adult patients in the US. Prior to 1996, abnormal 
TGs were an underappreciated lipid disorder in the US.1 However, over the past 
decade, TGs have gained prominence, both as an individual lipid measurement and 
for their effect on non-high-density lipoprotein cholesterol (non-HDL-C) levels.1,2 International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Although low-density lipoprotein cholesterol (LDL-C) is 
often used to assess dyslipidemia, it is now becoming clear 
that it is important to monitor and treat abnormal TG levels 
as well.3,4 Indeed, as an indirect measurement of apolipopro-
tein B (apo B)-containing TG-rich lipoproteins, the National 
Cholesterol Education Program (NCEP) Adult Treatment 
Panel III (ATP III) added non-HDL-C as a secondary goal 
of therapy in 2001.5 This represents an emerging challenge 
for all health care practitioners treating female patients, 
including gynecologists, an increasingly popular choice as 
the primary care provider for many women. The increas-
ingly fragmented approach to women’s primary health care 
(ie, relegating some primary care by generalists and other 
primary care by gynecologists) adds complexity to overall 
women’s health care, as it is unlikely that at any stage of life 
women receive comprehensive and systematic health care 
from only one provider.6
This article reviews the impact of elevated TGs in 
women and the importance of monitoring TG levels and 
other atherogenic surrogates in women. Guidelines for 
patient management are reviewed, as well as the evidence 
supporting the use of prescription omega-3-acid ethyl esters 
(P-OM3) as monotherapy for severe hypertriglyceridemia 
(TGs $ 500 mg/dL) and in combination with statins in 
patients with persistently high TGs (200–499 mg/dL). Other 
treatment strategies, including diet and lifestyle modifica-
tions, are also discussed or mentioned.
Methods
MedLine was searched for articles published through 
August 2009 using the terms “hypertriglyceridemia” 
and   “dyslipidemia”, with subheadings for “prevalence”, 
“women”, “treatment”, “guidelines”, “risk”, and “omega-3 
fatty acids”. Publications discussing the epidemiology of 
hypertriglyceridemia, coronary heart disease (CHD) risk, 
treatment guidelines for lipid management, or clinical trials 
involving P-OM3, were selected for review. The reference 
lists of relevant articles were also examined for additional 
citations.
Triglyceride metabolism
By facilitating trafficking of fatty acids (FAs), TGs play an 
important role in metabolism, serving as a molecular source 
of energy for muscles and other cells in the body. Excess FAs 
not needed for energy are reassembled into TGs and stored in 
adipose tissue. TGs, also known as triacylglycerols, comprise 
glycerol esterified with three FAs (acyl groups). TGs, along 
with other plasma-insoluble lipids such as   cholesterol, 
  cholesteryl ester, and phospholipids, are trafficked via 
protein-enwrapped particles called lipoproteins.7,8 TGs can 
be derived from two pathways, the exogenous (intestinal) 
pathway and the endogenous (hepatic-derived) pathway.7 
Dietary consumption and absorption of FAs and glucose 
influence intestinal and hepatic metabolism of TGs.9
In the exogenous pathway, lipases hydrolyze dietary TGs 
throughout the upper gastrointestinal tract. Once absorbed 
into enterocytes, FAs are reassembled into TGs and incor-
porated into large, apoB48-enwrapped, TG-rich lipoproteins 
called chylomicrons. Chylomicrons enter the lymphatic 
  system and ultimately the circulation, where they are exposed 
in muscular and adipocyte tissues to lipoprotein lipase (LPL), 
which hydrolyzes their core TGs, causing the release of FAs 
and surface phospholipids. The liver actively removes the 
remaining chylomicron remnants (TG-poor, cholesterol-rich 
particles) from circulation.10
In the endogenous pathway, hepatic TGs synthesized from 
FAs, and carbohydrate-derived glycerol and the other lipids, 
are packaged into apoB100-enwrapped very low-density 
lipoprotein (VLDL) particles.7 VLDL transports TGs from 
the liver to peripheral tissues, such as muscle and adipocytes.8 
TG-rich particles shrink during lipolysis, and phospholipids, 
as well as certain apolipoproteins (apo C-I and -III and apo 
E), are exchanged with high density lipoproteins (HDL) 
particles. The remaining, now smaller, VLDL particles 
are termed   remnants, or   intermediate-density lipoproteins 
(IDLs), most of which are then removed from circulation 
by the liver LDL receptors.10 The remaining smaller VLDLs 
and IDLs undergo further lipolysis via hepatic lipase and 
are converted to LDL particles.7,8 Because of its long half-
life of 2–3 days, the vast majority of apo B lipoproteins are 
LDLs.11,12 Increased numbers of apo B or LDL particles not 
cleared by hepatic LDL receptors have increased plasma 
residence time and may enter the arterial intima.13,14 Cho-
lesterol is also trafficked in multiple directions to and from 
tissues via HDL.10,15
In patients with elevated TGs, VLDL particles are 
increased in number and size and contain more lipids, 
  especially TGs.16 In insulin-resistant patients, these larger 
TG-rich VLDL particles have delayed lipolysis, which may 
be due to a lower affinity for lipase activity and tissue or 
hepatic receptors that promote the degradation and   clearance 
of VLDL particles.17 These TG-rich VLDL particles with 
increased plasma residence time transfer some of their 
core TG to HDL and LDL via cholesteryl ester transfer 
protein (CETP), in exchange for cholesteryl ester (CE).13,17 
CETP-mediated activity decreases the core CE content but International Journal of Women’s Health 2011:3
TG/Female
Mean values-different age-groups
TG/Male
Mean values-different age-groups
m
g
/
d
L
m
g
/
d
L
Decade Decade
20–29 30–39 40–49 50–59 60–69 >70 20–29 30–39 40–49 50–59 60–69 >70
227
209
190
173
155
136
118
100
82
227
213
195
1.77
159
141
123
105
Sweden
Sweden
Iran
Sweden
USA
Iran
Sweden
USA
USA
USA
Iran Iran
Figure 1 Influence of aging on TG levels of men and women in three cultures. All TG values between the ethnic groups are significant (P , 0/001) except between Sweden 
and the US (P = 0.65). In Iranians, the combination of high TG was associated with elevated apo B, suggesting that increased hepatic fatty acid flux may be an important driver 
of the increased apo B. The increased numbers of TG-rich VLDL result in relative enrichment of LDL and HDL in TG and depletion in cholesterol ester and therefore higher 
apo B and apo A-I than LDL-C and HDL-C, respectively. Copyright © 2009. elsevier. Reprinted with permission from Solhpour A, Parkhideh S, Sarrafzadegan N, et al. Levels 
of lipids and apolipoproteins in three cultures. Atherosclerosis. 2009;207(1):200–207.26
Abbreviations: Apo B, apolipoprotein B; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LDL-C, low-density 
lipoprotein cholesterol; TG, triglyceride; VLDL, very low-density lipoprotein.
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increases the core TG content of HDL and LDL particles. 
Subsequent exposure of TG-rich, CE-poor HDL particles 
and LDL particles to hepatic lipase leads to the formation 
of small, dense LDL particles and HDL particles.18–20 Small, 
dense HDL particles are more likely to be degraded with their 
surface apo A-I excreted in the urine, reducing the capacity 
for HDL-mediated cholesterol   clearance.15 Small, dense 
LDL particles are not readily cleared by LDL receptors and 
therefore accumulate, which leads to increased LDL particle 
(apo B) numbers.8,20
In patients with normal hepatic TG pools, VLDL par-
ticles are smaller in size and number, and CETP activity is 
decreased, lessening the transfer of TGs to LDL and HDL 
particles, resulting in greater LDL particle core cholesterol 
composition, which may increase LDL-C levels.7
Triglycerides in women
epidemiology
The classification for assessing CVD risk related to TG 
levels according to the NCEP ATP III defines fasting 
TGs , 150 mg/dL as normal, TG levels 150–199 mg/dL as 
moderately high risk, TG levels 200–499 mg/dL as high risk, 
and TG levels $500 mg/dL (severe   hypertriglyceridemia, 
also referred to as very high TGs) as very high risk.21 
  According to the National Health and Nutrition   Examination 
Survey (NHANES) 1999–2004, about 29.6% of US women 
(age 20 years and older) have hypertriglyceridemia 
(TGs . 150 mg/dL). In the US, severe hypertriglyceridemia 
(TGs $ 500 mg/dL) occurs in about 1.7% (3.8 million) of 
diagnosed patients, and in about 0.8% (1.2 million) of all 
US females.1 An analysis of the Framingham Heart Study 
showed that the 61% of women who had incident CHD had 
TGs . 200 mg/dL.22 Severe hypertriglyceridemia arises from 
multiple causes, including rare genetic mutations that reduce 
the expression of LPL and/or apo C-II (Fredrickson type I 
and V hyperlipidemia), as well as very poorly controlled 
or acute onset of diabetes, nephrosis, or certain drugs.21 
More modest increases in TGs in women are seen with 
insulin resistance, type 2 diabetes (affects about 19 million 
people in the US), pregnancy, obesity, high-carbohydrate 
diets, alcohol use, hypothyroidism, and metabolic disorders 
(especially the polycystic ovarian syndrome), as well as the 
use of some prescription drugs, including antipsychotics 
(clozapine, olanzapine), β-blockers (atenolol, metropolol), 
and   a  nti-inflammatories, among others.23,24
Changes in triglyceride levels  
in menopausal women
Metabolic changes associated with menopause and 
aging can be a major cause of abnormal lipid profiles 
in women.25 An analysis of subjects in the NHANES 
1999–2002 cohort reveals that although women have lower International Journal of Women’s Health 2011:3
Table  1  NCeP  ATP  III  goals  for  LDL-C  and  non-HDL-C  in 
patients with elevated TGs, stratified by CHD risk level20,41
Risk level LDL-C Non-HDL-Ca
CvD plus high-risk factors ,70 mg/dL ,100 mg/dL
CHD or CHD risk equivalent ,100 mg/dL ,130 mg/dL
Multiple (2+) risk factors ,130 mg/dL ,160 mg/dL
0–1 risk factors ,160 mg/dL ,190 mg/dL
Note: aNCeP ATP III recommends non-HDL-C as a secondary treatment goal in 
patients with TGs $ 200 mg/dL. Risk factors include age, smoking, hypertension, 
premature family history of CHD, and low HDL-C.
Abbreviations: CHD, coronary heart disease; CvD, cardiovascular disease; HDL-C, 
high-density  lipoprotein  cholesterol;  LDL-C,  low-density  lipoprotein  cholesterol; 
NCeP ATP III, National Cholesterol education Program Adult Treatment Panel III; 
TGs, triglycerides.
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TGs than men throughout most of their life, a reversal 
  happens in women above 60 years of age (Figure 1).26,27 
  Postmenopausal women tend to have higher levels of 
TGs compared with   premenopausal women.28 TGs can be 
significantly influenced by menopausal status and follicle-
stimulating hormone levels.29 Aging has also been shown 
to increase TG levels.29 These TG increases are likely asso-
ciated with insulin   resistance related to age, menopausal 
status, weight increase, and obesity.29,30 The transition 
through menopause is associated with selective deposition 
of visceral fat.31 Abdominal visceral fat deposition best 
predicts changes in lipid parameters and insulin sensitivity.32 
Increased LPL activity is observed after the withdrawal of 
estrogens,32 which leads to the elevation of the FAs locally 
and accumulation of abdominal fat.25
Clinical impact
TGs are a significant risk factor for CHD irrespective of 
LDL-C levels and other established risk factors.3,33 In   addition, 
the combination of enlarged waist circumference ($88 cm 
or 35 inches) and elevated TGs ($128 mg/dL) can also be 
a useful marker of CVD risk in postmenopausal   women.34 
Similar to elevated levels of fasting TGs, very high   levels 
of nonfasting TGs may also indicate the presence of 
increased numbers of atherogenic apo B particles, including 
remnant lipoproteins and LDL, which can increase CVD 
risk.35   Hypertriglyceridemia is also related to low HDL-C 
levels, another independent CVD risk factor, and both of 
these lipid abnormalities are components of the metabolic 
syndrome.3,36,37
Hypertriglyceridemia is the third leading cause of acute 
pancreatitis after gallstone disease and alcohol. Severe 
TG levels $1000 mg/dL are associated with approximately 
10% of all acute pancreatitis episodes and half of all cases 
of gestational pancreatitis. It has been suggested that high 
levels of circulating TG-rich lipoproteins are hydrolyzed by 
pancreatic lipase into FAs. The elevation in serum FAs may 
induce the formation of FAs, phospholipid micelles, and 
subsequent inflammation due to the disruption of platelets 
and the vascular endothelium. Hyperviscosity due to elevated 
serum FAs may also aggravate this condition.38
Reducing triglyceride levels  
in women
Goals of therapy
Plasma cholesterol measurements are strong predictors 
of atherogenesis.21 However, the measurement of apo 
B   provides an estimate of the total burden of particles 
  considered most atherogenic, and the use of apo B or LDL 
particle   concentrations has been shown to be a stronger 
predictor of CVD risk than any other lipid concentration.39 
LDL-C, VLDL-C (calculated as TG/5), and, in particular, 
non-HDL-C lipid concentrations serve as surrogates of 
apo B concentration.40 However, non-HDL-C is a better 
surrogate of all atherogenic particles than LDL-C, as it 
includes cholesterol within all apo B-containing particles.21 
The non-HDL-C value can be calculated easily by subtract-
ing the HDL-C value from the total cholesterol (TC) value 
and can be assessed in the nonfasting patient.2 Data from 
the Framingham Heart Study indicate that non-HDL-C is 
a better predictor of CVD risk than LDL-C, regardless of 
TG levels.40
According to NCEP ATP III guidelines (Table 1), in 
patients with hypertriglyceridemia (TGs 200–499 mg/dL), 
LDL-C is the primary target for therapy, with   non-HDL-C as a 
secondary treatment goal.21 LDL-C goals range from ,70 mg/
dL in very high-risk patients to ,100 mg/dL for patients with 
CHD or CHD equivalents and to 160 mg/dL for those without 
CHD risk factors.41 Non-HDL-C treatment goals are 30 mg/dL 
(which represents a normal VLDL-C level) higher than LDL-C 
goals stratified by CHD risk.21 In patients with severe hyper-
triglyceridemia (defined in guidelines as very high TGs [TGs 
$ 500 mg/dL]), lowering TGs is the first priority, and reducing 
CHD risk (LDL-C and non-HDL-C levels) is a secondary goal, 
once TG levels are reduced to ,500 mg/dL.4,21
The American Heart Association (AHA) guidelines to 
prevent CVD in women (Table 2) state that non-HDL-C 
of ,130 mg/dL is desirable.42 In a patient who has reached 
her LDL-C goal but still has a high level of non-HDL-C, 
indicating a high level of apo B particles, residual risk 
remains.39,44 For patients with cardiometabolic risk   factors, 
including diabetes, hypertriglyceridemia, and low HDL-C, 
the   American Diabetes Association (ADA) and American International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Table 2 Selected statements from American Heart Association 
guidelines for the prevention of coronary heart disease in women
Lifestyle changes Statement
Smoking cessation Do not smoke and avoid 
environmental tobacco smoke
Physical activity Minimum of 30 minutes of 
moderate-intensity physical activity 
on most, and preferably all, days of 
the week
Dietary intake A diet rich in fruits and vegetables; 
choose whole-grain, high-fiber 
foods; consume fish, especially 
oily fish, at least twice a week; 
limit intake of saturated fat to 10% 
of energy and, if possible, to 7%, 
cholesterol to 300 mg/d
Alcohol intake No more than one drink per day
Weight maintenance/reduction Women should maintain or lose 
weight through an appropriate 
balance of physical activity, caloric 
intake, and formal behavioral 
programs when indicated to 
maintain/achieve a BMI between 
18.5 and 24.9 kg/m2 and a waist 
circumference of 35 inches
Omega-3 fatty acids As an adjunct to diet, omega-3 fatty 
acids in capsule form (approximately 
850–1000 mg of ePA and DHA) 
may be considered in women with 
CHD, and higher doses (2–4 g) may 
be used for treatment of women 
with high triglyceride levels
Treatment goals
Major risk factor interventions
Lipid and lipoprotein levels:  
optimal levels and lifestyle
The following levels of lipids and 
lipoproteins in women should 
be encouraged through lifestyle 
approaches:
LDL-C , 100 mg/dL
HDL-C . 50 mg/dL 
Triglycerides , 150 mg/dL 
Non-HDL-C , 1360 mg/dL
Notes:  Copyright  ©  2007.  Wolters  Kluwer/Lippincott,  Williams  &  Wilkins. 
Reprinted with permission from Mosca L, Banka CL, Benjamin EJ, et al. Evidence-
based  guidelines  for  cardiovascular  disease  prevention  in  women:  2007  update. 
Circulation. 2007;115(11):1481–1501.42
Abbreviations:  BMI,  body  mass  index;  CHD,  coronary  heart  disease;  DHA, 
docosahexaenoic acid; ePA, eicosapentaenoic acid; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol.
College of Cardiology have established LDL-C,   non-HDL-C, 
and apo B treatment goals (Table 3) and state that in patients 
with cardiometabolic risk, pharmacological decisions 
should be made with consideration of their effect on apo 
B levels.39
Current management practices
During patient visits, physicians must be diligent in educating 
women regarding cardiovascular health, along with   informing 
women that regular lipid assessments and proper management 
of lipid abnormalities are an   important part of their over-
all health care. A recent national   telephone-based survey 
revealed that confusion generated by the media (ie, inconsis-
tent efforts by the media to faciliatate   cardiovascular health 
awareness campaigns) is a major barrier to cardiovascular 
health in women (49% of respondents). In addition, 36% 
of respondents do not perceive themselves to be at risk for 
CHD, and 25% of respondents reported that their health 
care provider did not discuss the importance of heart health. 
Approximately 20% of respondents also reported that 
health care providers did not clearly explain how they could 
improve their risk status.45 It is important that health care 
providers clearly explain cardiovascular risks to their female 
patients and also discuss how to reduce these risks through 
appropriate diet and lifestyle changes.46
Although reducing LDL-C, a surrogate of apo B, has been 
a focus of managing lipid-related risk, it may not address the 
apo B particles related to TG elevation, such as remnants, 
small LDL particles, and TG-rich LDL. Overlooking the 
rest of the lipid profile can lead to the underdiagnoses and 
undertreatment of atherogenic apo B particles, particularly 
in women.22,47 In the US, only about one-third of physicians 
accept and use non-HDL-C measurements.47 Increased 
efforts may be necessary to educate physicians about the 
importance of monitoring non-HDL-C in women. It is likely 
that the NCEP ATP IV , due for release in 2011, will elevate 
the importance of non-HDL-C.
Lifestyle and diet modification
Changes in lifestyle habits are first-line therapy for all 
lipid disorders, including elevated TGs, and include body 
Table  3  Summary  of  Lipid  and  Lipoprotein  treatment 
recommendations from ADA/ACCF39 and AACC.72
Treatment goals
Highest-risk 
level
LDL-C Non-HDL-C Apo B LDL-P
ADA/ACC ,70 mg/dL ,100 mg/dL ,80 mg/dL -
AACC , 70 mg/dL , 80 mg/dL - -
High-risk patients
ADA/ACC ,100 mg/dL ,130 mg/dL ,90 mg/dL -
AACC ,100 mg/dL ,120 mg/dL ,80 mg/dL 1100 nmol/L
Lower-risk patients
AACC ,130 mg/dL ,150 mg/dL 100 mg/dL 1400 nmol/L
Abbreviations: LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-
density lipoprotein cholesterol; Apo, apolipoprotein; LDL-P, LDL particle count;   
AACC, American Association of Clinical ChemistryInternational Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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can also help achieve goals,58 and bile acid sequestrants can 
be added if the TGs are ,200 mg/dL.21 Statin-treated patients 
who have not achieved non-HDL-C goals should be offered 
additional lifestyle modifications or a higher statin dose.21 
However, it should be noted that patients treated with statin 
monotherapy often meet LDL-C goals (61%) but may be less 
likely to meet both LDL-C and non-HDL-C goals (39%).57 
The addition of a fibrate, niacin, ezetimibe, or P-OM3 might 
be considered to help patients treated with a statin achieve 
non-HDL-C goals.21,58,59
For patients with severe hypertriglyceridemia (TGs $ 
500 mg/dL), therapeutic options recommended to lower 
TGs include 4 g/d P-OM3, fibrates, high doses of niacin, 
and, if needed, high doses of statins (both niacin and fibrates 
have cautionary regulatory labeling relative to their use with 
statins).21 Although elevated TGs should be treated promptly, 
no evidence from well-controlled, blinded studies has shown 
that decreasing TGs per se with P-OM3 4 g/d or any other 
medication reduces CVD risk.21,39
Prescription omega-3-acid  
ethyl esters for the treatment  
of severe hypertriglyceridemia
Monotherapy
For treatment of severe hypertriglyceridemia, only one 
prescription formulation of P-OM3 (Lovaza®, a registered 
trademark of Reliant Pharmaceuticals, Inc., a member of the 
GlaxoSmithKline group of companies, Research Triangle 
Park, NC, USA) is US Food and Drug Administration (FDA) 
approved. Each 1 g capsule contains at least 900 mg P-OM3 
(of which DHA comprises ∼375 mg and EPA ∼465 mg).60 
P-OM3 monotherapy is indicated as an adjunct to diet 
for adults only with severe hypertriglyceridemia (TGs $ 
500 mg/dL). The FDA-approved 4 g/d dose significantly 
lowers TG and non-HDL-C levels, which appears to be 
due primarily to VLDL-C reduction, in patients with severe 
hypertriglyceridemia.61–63
The effects of P-OM3 4 g/d monotherapy for lowering TGs 
in adult patients (N = 84; 42 on P-OM3 and 42 on   placebo) with 
severe hypertriglyceridemia were evaluated in two randomized, 
double-blind, placebo-controlled, parallel-group studies of 6 and 
16 weeks’ duration.61,62 In a pooled analysis of both monotherapy 
studies, baseline TG levels ranged from 500 mg/dL to 2000 mg/
dL with a median TG concentration of 792 mg/dL. Baseline 
median HDL-C and calculated LDL-C levels in these patients 
were 23 mg/dL and 100 mg/dL, respectively.61 Treatment with 
4 g/d P-OM3 resulted in median reductions of TGs, VLDL-C, 
weight control, regular physical activity, smoking cessation, 
  restriction of alcohol use (in selected persons), and avoidance 
of high-carbohydrate diets.21 The AHA recommends that 
women should accumulate at least 30 minutes of moderately 
intense physical activity (eg, brisk walking) preferably daily, 
and more exercise to lose weight.42
The NCEP ATP III dietary guidelines call for caloric 
intake that meets daily needs without exceeding them, lim-
ited consumption of saturated and monounsaturated fats 
and carbohydrates, and increased consumption of fiber and 
plant stanols/sterols.21 However, more current evidence has 
  questioned dietary supplementation with plant sterols.48 
As part of adopting a healthy diet, multiple health associations, 
including the AHA,49 the ADA,50 and the US   Departments of 
Agriculture and Health and Human Services,51 recommend 
regular consumption of fatty fish (salmon, tuna, herring, 
sardines, mackerel, and trout) that provides the omega-3 
FAs docosahexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA). Eating 8 oz of fatty fish in a week provides an   average 
of ∼500 mg/d DHA and EPA.52 In 1992, the AHA further 
  recommended 2–4 g/d DHA and EPA (under a   physician’s 
care) for patients trying to lower TGs.53 However, newer data 
show that P-OM3 have a threshold effect on lowering TGs, 
and a dose of 4 g/d is required. Like other TG-modulating 
drugs, greater reductions are seen in those with high TGs 
concentrations of .500 mg/dL.54 Obtaining 4 g/d of DHA 
and EPA through diet alone would require the consumption 
of ∼32–64 oz of fatty fish in a week,54 which may be an imprac-
tical solution for many patients. In addition, due to concerns 
regarding mercury and other environmental contaminants in 
dietary fish, supplementation may be a more reasonable way 
to provide fish oil to patients.55 OM3-FAs are also available 
in a variety of nonregulated dietary supplements. The use of 
purified and concentrated P-OM3 (four capsules/day, 1 g each) 
for patients with severe hypertriglyceridemia may improve 
compliance and reliability compared with dietary supplements 
containing fish oil, which may contain as little as 300 mg of 
DHA and EPA.55,56
Pharmacologic treatment options
In spite of dietary and lifestyle modifications, some patients 
require the use of medication to achieve non-HDL-C and TG 
treatment goals. In patients with multiple lipid abnormali-
ties and TGs , 500 mg/dL, statins, at the dose required to 
achieve risk-adjusted goals, are recommended as first-line 
therapy after lifestyle interventions have been offered.21 As an 
alternative option, lower-dose statins in combination with 
fibrates or niacin can be used. Adding ezetimibe to statins International Journal of Women’s Health 2011:3
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Figure 2 effect of P-OM3 vs placebo on lipid parameters in patients with severe hypertriglyceridemia. P values for lipid changes were TGs (P , 0.00001), vLDL-C 
(P , 0.0001), HDL-C (P = 0.014), and LDL-C (P = 0.0014). Copyright© 2009. GlaxoSmithKline group of companies. Adapted with permission from Copyright© 2009. 
GlaxoSmithKline group of companies. Adapted with permission from LOVAZA [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2009.60
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; P-OM3, prescription omega-3-acid ethyl esters; TG, triglyceride; 
vLDL-C, very low-density lipoprotein cholesterol.
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and non-HDL-C of 44.9%, 41.7%, and 13.8%, respectively, and 
increases in LDL-C and HDL-C of 44.5% and 9.1%, respectively, 
from baseline levels (Figure 2).61 Patients treated with placebo 
had a median TG increase of 6.7% and reductions in VLDL-C, 
non-HDL-C, LDL-C, and HDL-C of 0.9%, 3.6%, 4.8%, and 
0.0%,   respectively, from baseline levels (Figure 2).61
Patients included in this pooled analysis had type IV or V 
hypertriglyceridemia, characterized by elevated cholesterol 
and TG levels associated with increased concentration of 
VLDL, and decreased HDL-C and LDL-C.61,62 Significant 
TG reductions in patients with hypertriglyceridemia are often 
accompanied by similar reductions in VLDL-C. LDL-C may 
increase in these patients, presumably due to more effec-
tive and rapid lipolysis and clearing of VLDL and IDL.63 
Reduction in VLDL-TGs reduces CETP activity, resulting 
in larger and more normally composed (more   CE-rich, 
TG-poor) LDLs and HDLs, which also helps explain the rise 
in LDL-C and HDL-C and decrease in VLDL-C. This can 
also result in a net reduction in the aggregate   levels of non-
HDL-C. The largest increases in LDL-C can be expected to 
occur in patients with the highest baseline TG levels prior to 
P-OM3 therapy.63 A similar LDL-C increase of 45% has been 
observed when fenofibrate was used to treat patients with 
type IV and V hypertriglyceridemia.64 Despite the reduc-
tion in VLDL-C, there is little change in apo B   levels with 
P-OM3 therapy.59,65 As with any lipid-regulating   product, 
LDL-C levels should be monitored periodically during 
therapy with P-OM3.60
Combination therapy with statins
Patients with elevated TGs typically have an increase in 
atherogenic VLDL remnants. Therefore, the residual risk 
in people with high TG levels cannot be accounted for by 
LDL-C measurements alone and should be monitored by 
measuring non-HDL-C (VLDL-C+LDL-C).2,21 In patients 
with hypertriglyceridemia (TGs 200–499 mg/dL), NCEP 
ATP III guidelines state that LDL-C is the primary goal, with 
non-HDL-C as a secondary target for therapy.21 When LDL-C 
is not significantly elevated, the goal for non-HDL-C with 
TG-lowering agents can be obtained more easily.21
Studies have also demonstrated that the addition of 
P-OM3 to statin therapy leads to further reductions in 
non-HDL-C. In a randomized, placebo-controlled study, 
COMBOS (Combination of Prescription Omega-3 Plus 
  Simvastatin), patients (N = 254) who had attained a mean 
LDL-C level below or within 10% of the patient’s NCEP goal 
with persistently high TGs (200–499 mg/dL) while taking 
simvastatin 40 mg/dL for 8 weeks were randomized to add 
P-OM3 4 g/d or placebo to their ongoing simvastatin therapy 
for an additional 8 weeks.59 At baseline, in patients treated 
with P-OM3, median TG, LDL-C, and non-HDL-C levels 
were 268 mg/dL, 91 mg/dL, and 137 mg/dL, respectively. 
At the end of therapy, adding P-OM3 to the simvastatin 
  treatment regimen reduced median non-HDL-C by 9% 
(vs 2.2% with placebo; P , 0.001; Figure 3).59 Subjects 
treated with P-OM3 also had a greater decrease in median 
apo B   concentrations beyond that induced by the statin alone International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
94
Dayspring
(4.2% vs 1.9%; P = 0.023).59 An open-label extension study 
in this persistently high TG (200–499 mg/dL) cohort was 
conducted to analyze the long-term safety and efficacy of sim-
vastatin 40 mg/dL and P-OM3 4 g/d combination therapy for 
up to 24 months.66 Eligible patients included those who com-
pleted the multicenter, randomized, placebo-controlled, dou-
ble-blind, parallel-group study.66 “Switchers” were patients 
who received placebo+simvastatin who were switched to 
P-OM3+simvastatin (n = 100). “Nonswitchers” were patients 
who were assigned P-OM3+simvastatin in COMBOS who 
remained on their original therapy (n = 88).66 The difference 
between switchers and nonswitchers in median percentage 
change in non-HDL-C from COMBOS end of treatment to 
month 4 of the extension study was the primary endpoint of 
this study.66 There was a greater response among switchers 
at month 4. Median percentage change in non-HDL-C from 
end of treatment was -9.4% versus 0.9% for switchers and 
nonswitchers (P , 0.001), respectively.66 Median percentage 
change for switchers and nonswitchers combined at months 
4 and 12 was −8.3% and 7.3%, respectively. At month 24, 
the median percent change in non-HDL-C for the combined 
groups was −8.9%.67 Data indicate that sustained reductions 
in non-HDL-C occurred with longer-term treatment with 
P-OM3+simvastatin.66
An additional analysis of subjects from the original 
trial, examining the effects of P-OM3 4 g/d cotherapy with 
simvastatin 40 mg/d on lipoprotein particle concentrations, 
revealed that the addition of P-OM3 significantly reduced 
mean VLDL particle size and increased LDL particle size 
compared with placebo (P , 0.006 for both). HDL particle 
size was not altered in these subjects. The total concentrations 
of VLDL particles or LDL particles relative to placebo were 
not significantly changed; however, large VLDL particle and 
IDL particle concentrations were lowered (P , 0.01 for both). 
Total LDL-P was not affected, but the large LDL particle 
concentration (LDL-P) was increased and small LDL-P was 
reduced compared with placebo (P , 0.0001).67 Remnant-like 
particle cholesterol, apo C-III, and Lp-PLA2 concentrations 
(factors associated with increased atherogenesis and CVD 
risk) were reduced compared with placebo (all P , 0.003),67 
the effects of which are consistent with those typically seen in 
hypertriglyceridemic subjects.68 It is unknown which of these 
effects, if any, represent the direct effect of P-OM3.
Simultaneous initiation of simvastatin and P-OM3 
  treatment can also lead to a greater reduction in non-HDL-C 
than treatment with simvastatin alone. A randomized, 
  placebo-controlled trial was conducted in which 39 patients 
with persistently high TGs (200–600 mg/dL) were given 
simvastatin 20 mg/d plus P-OM3 4 g/d or placebo and then 
crossed over to the other treatment after 6 weeks.69   Cotherapy 
with simvastatin plus P-OM3, when compared with 
  simvastatin plus placebo, produced greater median reductions 
in TGs (43.6% vs 28.7%; P , 0.001), TC (31% vs 26.4%; 
P , 0.01), and non-HDL-C (40% vs 34.3%; P , 0.001), 
whereas P-OM3 did not provide additional benefits for 
LDL-C (37.2% vs 38.4%).69 There was no difference in 
median apo B reduction between simvastatin and P-OM3 
treatment when compared with simvastatin plus placebo.69
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Figure 3 Response to the addition of P-OM3 4 g/d to ongoing simvastatin 40 mg/d therapy in patients with hypertriglyceridemia (TGs $ 200 mg/dL and #499 mg/dL). values 
for differences of non-HDL-C, HDL-C, TGs, and VLDL-C between POM3 and placebo were all significant at P , 0.001 and for apo B P = 0.023. The LDL-C differences were 
not significant. Copyright © 2007. Elsevier. Adapted with permission from Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty 
acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(7):1354–1367.59
Abbreviations: Apo B, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; P-OM3, prescription omega-3-acid ethyl 
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In an open-label extension of this study, 14 participants 
were treated with P-OM3 4 g/d plus simvastatin 80 mg/d 
for another 6 weeks.70 The increase in statin dosage led to a 
further reduction in non-HDL-C (51.0% with P-OM3 plus 
simvastatin 80 mg/d vs 40.8% with P-OM3 plus   simvastatin 
20 mg/d; P , 0.05) without affecting TGs (58.6% with 
P-OM3 plus simvastatin 80 mg/d vs 54.7% with P-OM3 plus 
simvastatin 20 mg/d).70
In addition, the effects of adding P-OM3 or placebo to 
escalating doses of atorvastatin (10–40 mg/d) on   non-HDL-C 
and TG levels were assessed in 243 patients with baseline 
non-HDL-C . 160 mg/dL and TGs 250–599 mg/dL.71 
Patients received escalating doses of open-label ator-
vastatin according to the following dosing schedule: 
weeks 0–8 = 10 mg/d, weeks 9–12 = 20 mg/d, and weeks 
13–16 = 40 mg/d. Patients were blinded with respect to 
receiving P-OM3 4 g/d or placebo for 16 weeks. P-OM3 plus 
atorvastatin 10, 20, and 40 mg/day led to 6.5% (P = 0.0002), 
7.9% (P , 0.0001), and 4.1% (P = 0.0007) greater reductions 
in median   non-HDL-C when compared with placebo plus the 
same doses of atorvastatin at the end of 8, 12, and 16 weeks, 
respectively. In addition, P-OM3 plus atorvastatin reduced 
median TC, TGs, and VLDL-C and increased HDL-C levels 
to a significantly greater extent than placebo plus atorvastatin. 
Non-HDL-C efficacy was also noninferior to doubling the 
statin dose in patients receiving P-OM3 plus atorvastatin.71 
The results to date demonstrate that treatment with P-OM3 
is efficacious and well tolerated as monotherapy or as part of 
a combination therapy to reduce TG levels in patients with 
hypertriglyceridemia.
Conclusion
Hypertriglyceridemia is a common lipid abnormality in the 
US that becomes more prevalent in women after menopause. 
Additional metabolic influences, including aging, central 
visceral obesity, and insulin resistance, can also negatively 
impact a woman’s lipid profile. Treatment of severe hyper-
triglyceridemia (TGs $ 500 mg/dL) should be a priority 
for all affected patients. Dietary and lifestyle interventions, 
including weight control, regular physical activity, smoking 
cessation, restricted alcohol use, and low-carbohydrate diets 
with increased intake of oily fish, represent the first-line 
option for therapy. In many cases, patients with severe hyper-
triglyceridemia require pharmacologic intervention. P-OM3 
and fibrates are both FDA-approved options for the treatment 
of severe hypertriglyceridemia in adult patients. As discussed 
in the previous paragraphs, P-OM3 has been shown to be 
well tolerated and effective as monotherapy for reducing TG 
levels in patients with severe hypertriglyceridemia. Primary 
care physicians and obstetricians/gynecologists assuming a 
primary care role should discuss regular lipid panel testing 
with their patients. The NCEP recommends monitoring lipid 
profiles every 5 years unless the profile is abnormal, then 
more frequent monitoring is called for, which may include 
lipoprotein testing in patients with cardiometabolic risk. 
Regular evaluations of female patients’ lipid parameters, 
including TGs and non-HDL-C, as well as apo B and LDL 
particle concentrations, will allow for more comprehensive 
evaluation and treatment of lipid disorders in this population, 
which has historically been undertreated.
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